Cost-effectiveness of Levosimendan in Patients With Acute Heart Failure
| Autor: | Bruno Brasolin, Noemi Bruno, Carmen Caira, Francesco Fedele, Alessandra D'Ambrosi, Massimo Mancone |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Inotrope medicine.medical_specialty Cardiotonic Agents Cost effectiveness Cost-Benefit Analysis Patient Readmission Quality of life Dobutamine Internal medicine medicine Humans Infusions Intravenous Simendan Aged Retrospective Studies Heart Failure Pharmacology Dose-Response Relationship Drug business.industry Mortality rate Hydrazones Levosimendan Length of Stay Middle Aged medicine.disease Pyridazines Survival Rate Heart failure Acute Disease Cardiology Population study Female acute heart failure hospitalization costs inodilator therapy rehospitalization rate survival Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 58:363-366 |
| ISSN: | 0160-2446 |
| Popis: | Heart failure is a major public health problem because of its high prevalence and impact on mortality, morbidity, quality of life, and social costs. The aim of this analysis was to estimate the effects of the novel inodilator levosimendan versus standard inotropic therapy (ST) of dobutamine in acute heart failure. A study population of 292 patients with acute heart failure was derived from an observational registry of patients referred to our department. Of these, 147 patients received iv levosimendan (0.05-0.1 μg·kg·min for 24 hours), and 145 patients were treated with ST. Duration of hospitalization, survival at 1 month, and the rehospitalization rate during the year after the index hospitalization were evaluated. Cost-effectiveness analysis was performed. The mean length of hospitalization was 12.08 and 13.57 days in the levosimendan and ST groups, respectively (P < 0.05). Rehospitalization rates were lower in the levosimendan group at 6 months (1.44% vs. 2.3%; P < 0.05) and 12 months (7.6% vs. 14.3%; P < 0.05). Mortality rate at 1 month was 2.1% versus 6.9% in the levosimendan and ST groups, respectively (P < 0.05). The per-capita cost of treatment with levosimendan was €78.86 higher than that with ST during the first hospitalization but €280.22 lower when the rehospitalization rate was considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|